Sesen Bio, Inc.

SESN NASDAQ
1.170
-0.040
-3.28%
After Hours: 1.180 +0.01 +0.85% 17:09 08/22 EDT
Open
1.230
Prev Close
1.220
High
1.250
Low
1.160
Volume
1.13M
Avg Vol (3M)
2.55M
52 Week High
2.600
52 Week Low
0.6609
% Turnover
1.11%
Market Cap
118.48M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Sesen Bio, Inc. SESN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Sesen Bio, Inc., formerly Eleven Biotherapeutics, Inc., is a late-stage clinical company that provides targeted protein therapeutics (TPT) platform. The Company is focused on developing antibody-drug conjugate (ADC) therapies for the treatment of cancer. Its product pipeline includes Vicinium, Vicinium in combination with checkpoint inhibator, durvalumab, and VB6-845d. The Company’s lead program, Vicinium, is a fusion protein in Phase III development for the treatment of non-muscle invasive bladder cancer (NMIBC). It targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent cytotoxin, Pseudomonas Exotoxin A (ETA) directly to cancer cells.
MORE >

Recently

Name
Price
%Change